Literature DB >> 11879366

Two-year remission and subsequent relapse in children with newly diagnosed epilepsy.

A T Berg1, S Shinnar, S R Levy, F M Testa, S Smith-Rapaport, B Beckerman, N Ebrahimi.   

Abstract

PURPOSE: Although remission is the ultimate measure of seizure control in epilepsy, and epilepsy syndrome should largely determine this outcome, little is known about the relative importance of syndrome versus other factors traditionally examined as predictors of remission or of relapse after remission. The purpose of this study was to examine remission and relapse with respect to the epilepsy syndrome and other factors traditionally considered with respect to seizure outcome.
METHODS: A prospectively identified cohort of 613 children with newly diagnosed epilepsy was assembled and is actively being followed to determine seizure outcomes. Epilepsy syndrome and etiology were classified at diagnosis and again 2 years later. Remission was defined as 2 years completely seizure-free, and relapse as the recurrence of seizures after remission. Multivariable analysis was performed with the Cox proportional hazards model.
RESULTS: Five hundred ninety-four of the original 613 children were followed > or = 2 years (median follow-up, 5 years). Remission occurred in 442 (74%), of whom 107 (24%) relapsed. On multivariable analysis, idiopathic generalized syndromes and age at onset between 5 and 9 years were associated with a substantially increased remission rate, whereas remote symptomatic etiology, family history of epilepsy, seizure frequency, and slowing on the initial EEG were associated with a decreased likelihood of attaining remission. Young onset age (<1 year) and seizure type were not important after adjustment for these predictors. Relapses occurred more often in association with focal slowing on the initial EEG and with juvenile myoclonic epilepsy. Benign rolandic epilepsy and age at onset <1 year were associated with markedly lower risks of relapse. About one fourth of relapses were apparently spontaneous while the child was taking medication with good compliance, and more than half occurred in children who were tapering or had fully stopped medication.
CONCLUSIONS: A large proportion of children with epilepsy remit. Symptomatic etiology, family history, EEG slowing, and initial seizure frequency negatively influence, and age 5-9 years and idiopathic generalized epilepsy positively influence the probability of entering remission. Factors that most influence relapse tend to be different from those that influence remission.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11879366     DOI: 10.1046/j.1528-1157.2001.21101.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  Relative Seizure Relapse Risks Associated with Antiepileptic Drug Withdrawal After Different Seizure-Free Periods in Adults with Focal Epilepsy: A Prospective, Controlled Follow-Up Study.

Authors:  Xinshi Wang; Ruqian He; Rongyuan Zheng; Siqi Ding; Yi Wang; Xueying Li; Yingjie Hua; Qingyi Zeng; Niange Xia; Zhenguo Zhu; Patrick Kwan; Huiqin Xu
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Scalp recorded spike ripples predict seizure risk in childhood epilepsy better than spikes.

Authors:  Mark A Kramer; Lauren M Ostrowski; Daniel Y Song; Emily L Thorn; Sally M Stoyell; McKenna Parnes; Dhinakaran Chinappen; Grace Xiao; Uri T Eden; Kevin J Staley; Steven M Stufflebeam; Catherine J Chu
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

3.  A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: cryptogenic epilepsy is probably not symptomatic epilepsy.

Authors:  Elaine C Wirrell; Brandon R Grossardt; Elson L So; Katherine C Nickels
Journal:  Epilepsia       Date:  2011-02-14       Impact factor: 5.864

4.  Infantile spasms is associated with deletion of the MAGI2 gene on chromosome 7q11.23-q21.11.

Authors:  Christian R Marshall; Edwin J Young; Ariel M Pani; Mary-Louise Freckmann; Yves Lacassie; Cédric Howald; Kristi K Fitzgerald; Maarit Peippo; Colleen A Morris; Kate Shane; Manuela Priolo; Masafumi Morimoto; Ikuko Kondo; Esra Manguoglu; Sibel Berker-Karauzum; Patrick Edery; Holly H Hobart; Carolyn B Mervis; Orsetta Zuffardi; Alexandre Reymond; Paige Kaplan; May Tassabehji; Ronald G Gregg; Stephen W Scherer; Lucy R Osborne
Journal:  Am J Hum Genet       Date:  2008-06-19       Impact factor: 11.025

5.  Simultaneous Electroencephalography and Functional Magnetic Resonance Imaging and the Identification of Epileptic Networks in Children.

Authors:  Thomas C Maloney; Jeffrey R Tenney; Jerzy P Szaflarski; Jennifer Vannest
Journal:  J Pediatr Epilepsy       Date:  2015-08-18

6.  Convulsive status epilepticus and health-related quality of life in children with epilepsy.

Authors:  Mark A Ferro; Richard F M Chin; Carol S Camfield; Samuel Wiebe; Simon D Levin; Kathy N Speechley
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

7.  Efficacy of vagus nerve stimulation in brain tumor-associated intractable epilepsy and the importance of tumor stability.

Authors:  Kunal S Patel; Nelson Moussazadeh; Werner K Doyle; Douglas R Labar; Theodore H Schwartz
Journal:  J Neurosurg       Date:  2013-04-19       Impact factor: 5.115

Review 8.  Sudden unexpected death in epilepsy. Potential role of antiepileptic drugs.

Authors:  Dale C Hesdorffer; Torbjorn Tomson
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

9.  Efficacy of vagus nerve stimulation as a treatment for medically intractable epilepsy in brain tumor patients. A case-controlled study using the VNS therapy Patient Outcome Registry.

Authors:  Kunal S Patel; Douglas R Labar; Charles M Gordon; Kevin H Hassnain; Theodore H Schwartz
Journal:  Seizure       Date:  2013-06-12       Impact factor: 3.184

10.  What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis?

Authors:  Elaine C Wirrell; Lily C-L Wong-Kisiel; Jay Mandrekar; Katherine C Nickels
Journal:  Epilepsia       Date:  2013-04-03       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.